Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Prevalence of and factors associated with depression among people living with HIV in France.

Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group.

HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14.

PMID:
27625202
2.

Analysis of endovascular therapy for femoropopliteal disease with the Supera stent.

Montero-Baker M, Ziomek GJ, Leon L, Gonzales A, Dieter RS, Gadd CL, Pacanowski JP Jr.

J Vasc Surg. 2016 Oct;64(4):1002-8. doi: 10.1016/j.jvs.2016.04.053. Epub 2016 Jul 18.

PMID:
27444365
3.

Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.

Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

J Int AIDS Soc. 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095. eCollection 2016.

4.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
5.

Has the employment status of people living with HIV changed since the early 2000s?

Annequin M, Lert F, Spire B, Dray-Spira R; VESPA2 Study Group.

AIDS. 2015 Jul 31;29(12):1537-47. doi: 10.1097/QAD.0000000000000722.

PMID:
26244393
6.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

7.

Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort.

Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; FHDH-ANRS CO4.

Int J Cancer. 2015 Nov 15;137(10):2443-53. doi: 10.1002/ijc.29603. Epub 2015 Jun 2.

8.

Women living with HIV still lack highly effective contraception: results from the ANRS VESPA2 study, France, 2011.

Maraux B, Hamelin C, Bajos N, Dray-Spira R, Spire B, Lert F; Vespa2 study group.

Contraception. 2015 Aug;92(2):160-9. doi: 10.1016/j.contraception.2015.04.010. Epub 2015 May 2.

PMID:
25940932
9.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

10.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27.

PMID:
25723557
11.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

12.

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.

Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D; Duration of Treatment for Spondylodiscitis (DTS) study group.

Lancet. 2015 Mar 7;385(9971):875-82. doi: 10.1016/S0140-6736(14)61233-2. Epub 2014 Nov 5.

PMID:
25468170
13.

Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4).

AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382.

PMID:
25265077
14.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

15.

Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).

Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553. Epub 2014 Apr 14.

PMID:
24731158
16.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

17.

The spectrum of chronic CD8+ T-cell expansions: clinical features in 14 patients.

Ghrenassia E, Roulin L, Aline-Fardin A, Marzac C, Féger F, Gay J, Pacanowski J, Hertig A, Coppo P.

PLoS One. 2014 Mar 11;9(3):e91505. doi: 10.1371/journal.pone.0091505. eCollection 2014.

18.

Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis.

Thomas L, Mailles A, Desestret V, Ducray F, Mathias E, Rogemond V, Didelot A, Marignier S, Stahl JP, Honnorat J; Steering Committee and Investigators Group.

J Infect. 2014 May;68(5):419-25. doi: 10.1016/j.jinf.2013.12.001. Epub 2013 Dec 17.

PMID:
24355654
19.

Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.

Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Costagliola D, Grabar S; French Hospital Database on HIV–ANRS CO4 Cohort.

Clin Infect Dis. 2013 Dec;57(11):1638-47. doi: 10.1093/cid/cit497. Epub 2013 Jul 29.

PMID:
23899679
20.

Encephalitis due to Mycobacterium tuberculosis in France.

Honnorat E, De Broucker T, Mailles A, Stahl JP; le comité de pilotage et groupe des investigateurs.

Med Mal Infect. 2013 Jun;43(6):230-8. doi: 10.1016/j.medmal.2013.05.003. Epub 2013 Jun 28.

PMID:
23816146

Supplemental Content

Loading ...
Support Center